FDA says some data testing Novartis’ $2 million gene therapy was manipulated
NEW YORK (Reuters) – The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis’ more than $ 2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market. FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is… Read More »